Medicines as a service a new commercial model for big pharma in the postblockbuster world

The pharmaceutical industry can reconfigure its considerable resources to develop innovative and meaningful business models that are based on services related to prescription drugs for chronic conditions. We argue that such innovation beyond the pill is consistent with the core capabilities of large...

Full description

Main Author: Mattke, Soeren
Corporate Author: RAND Health
Other Authors: Klautzer, Lisa, Mengistu, Tewodaj
Format: eBook
Language:English
Published: Santa Monica, CA RAND Health [2012], 2012
Series:Occasional paper
Subjects:
Online Access:
Collection: JSTOR Open Access Books - Collection details see MPG.ReNa
Summary:The pharmaceutical industry can reconfigure its considerable resources to develop innovative and meaningful business models that are based on services related to prescription drugs for chronic conditions. We argue that such innovation beyond the pill is consistent with the core capabilities of large pharmaceutical companies and has the potential to achieve profit levels similar to those of its traditional models. Our argument is based on the fact that, although effective medicines for most chronic conditions exist, access and adherence to medicines are far from what would be needed to achieve full treatment efficacy. Therefore, value can be created by getting and keeping more patients on their drugs, and innovative business models would allow pharmaceutical companies to capture that value
Item Description:Title from PDF caption
Physical Description:1 PDF file (11 pages)
ISBN:0833076469
9780833076465